menu
    • menu
    [{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Pint Pharma"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"OrphanDC","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"AUSTRIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ OrphanDC","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ OrphanDC"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pint Pharma \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ PharmaEssentia"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Ropeginterferon-Alpha-2B","moa":"IFNAR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"Pint Pharma \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Pint Pharma"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Pint Pharma

    Menu

    Pint Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pint Pharma Wins INVIMA Approval For ORLADEYO In HAE Prevention

                            Details : Orladeyo (berotralstat HCl) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2025

                            Lead Product(s) : Berotralstat Hydrochloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : PharmaEssentia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pint Pharma Secures ANVISA Approval for BESREMI® in Polycythemia Vera Treatment

                            Details : BESREMi (ropeginterferon alfa-2b-njft) targets IFNAR to initiate downstream signaling through the activation of JAK1 and TYK2 and STAT proteins. It is approved for adult patients with PV.

                            Product Name : Besremi

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : PharmaEssentia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO® for HAE Prevention in Peru

                            Details : Orladeyo (berotralstat), plasma kallikrein inhbitor, is the first oral therapy designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO® (berotralstat) for HAE Prevention in Mexico for Ages 12+

                            Details : Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2024

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pint Pharma Approves ORLADEYO (berotralstat) for HAE Prevention in Brazil for Ages 12+

                            Details : Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in patients aged 12 and older.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegcetacoplan

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : OrphanDC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Empaveli is the First Treatment for PNH that Binds to the Complement Protein C3

                            Details : Empaveli (pegcetacoplan) is the first treatment for PNH that binds to the complement protein C3, which is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

                            Product Name : Empaveli

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : Pegcetacoplan

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : OrphanDC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioCryst Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

                            Details : Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : BioCryst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin...

                            Details : Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, i...

                            Product Name : Besremi

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 06, 2023

                            Lead Product(s) : Ropeginterferon-Alpha-2B

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed

                            Pint Pharma

                            Austria arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO (berotralstat) in Latin America

                            Details : Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.

                            Product Name : Orladeyo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : Berotralstat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : BioCryst Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth